Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK vaccine ‘protects against lesions from HPV 16 and 18’

GSK vaccine ‘protects against lesions from HPV 16 and 18’

18th April 2007

GlaxoSmithKline (GSK) has presented data to the annual meeting of the American Association for Cancer Research showing that its cervical cancer candidate vaccine Cervarix has shown 100 per cent protection against precancerous lesions arising from human papillomavirus (HPV) types 16 and 18 for over five years.

Furthermore, irrespective of the type of cancer-causing virus, the vaccine also exhibited 38 per cent efficacy against abnormal pap smears and 68 per cent efficacy against precancerous lesions.

GSK comments that this trial data implies that broader protection may be provided by the vaccine beyond HPV types 16 and 18.

Dr Hugues Bogaerts, vice-president of worldwide medical affairs, HPV vaccines at GSK, said: “The results of this study confirm our confidence in our cervical cancer candidate vaccine, which includes a noel proprietary adjuvant system, called AS04, intended to enhance immune response and increase duration of protection.”

He added that the best method to prevent individuals from contracting cervical cancer is to use a combination of vaccine use to protect against the most common virus types that cause cancer together with routine screening.

In June 2006, GSK announced the release of trial data showing that Cervarix is both “highly immunogenic” and well tolerated in women over the age of 25.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.